ESAGOES Tyropod Fifty

Total Page:16

File Type:pdf, Size:1020Kb

ESAGOES Tyropod Fifty United States Patent 15 3,689,571 Regan et al. (45) Sept. 5, 1972 54 FLUORINATED ETHER 56) References Cited (72) Inventors: Bernard M. Regan; John C. Long- UNITED STATES PATENTs street, both of Chicago, Ill. 3,476,860 1 1/1969 Croix et al..........260/614 FX (73) Assignee: Baxter Laboratories, Inc., Morton 3,346,448 10/1967 Gilbert et al........... 260/614 F Grove, Ill. 22 Filed: July 31, 1970 OTHER PUBLICATIONS Mitsch et al., J. Heterocyclic Chem., Vol. 2, (1965) 21 Appl. No.: 60,132 pp. 152- 156 Related U.S. Application Data 63 Continuation-in-parts of Ser. No. 771,365, Oct. Primary Examiner-Howard T. Mars 28, 1968, abandoned. Attorney-Scott J. Meyer (52) U.S. C. ............................... 260/614 F, 424/342 57 ABSTRACT ESAGOES Tyropod1,1,1,3,3,3-hexafluoro-2-propyl ether, usefulfifty as an anesthetic agent. 1 Claim, No Drawings 3,689,571 1. 2 FLUORNATED ETHER are formed with the present fluoromethyl 1,1,1,3,3,3- hexafluoro-2-propylether. CROSS-REFERENCE TO RELATED APPLICATION The outstanding utility of the fluoromethyl This is a continuation-in-part of co-pending applica 1,1,1,3,3,3-hexafluoro-2-propyl ether of the present in tion Ser. No. 771,365, filed Oct. 28, 1968 and now 5 vention is further highlighted by comparison with abandoned. isomers of that compound which do not have this utili This invention relates to the fluorinated ether, ty. For example, the compound CHsOCF(CF), was fluoromethyl 1,1,1,3,3,3-hexafluoro-2-propyl ether, found to be non-anesthetic up to 8 percent by volume having the structure CHF-O-CH(CF)2. in oxygen, which means that it would burn at its In recent years, several fluorinated ethers have been 10 anesthetic concentration since its lower flammability found to have useful anesthetic properties, notably limit is about 7 percent to 8 percent. Another isomer, methoxyflurane, CHOCFCH; fluroxene, CFCHOC the trifluoromethyl 2,2,3,3-tetrafluoropropyl ether of H = CH, roflurane; CHOCFCHBrF; and ethrane, Aldridge and Shepherd, J. Org, Chem., Vol. 29, pages CHFOCFCHCIF. 11-15 (1964), has been shown to cause violent convul With the recent availability of various polyhalo 15 sions and deaths in mice at a concentration as low as isopropanols, which serve as excellent starting materi 0.5 percent. Yet another isomer, CHFOCHCFCF is als for the corresponding methyl ethers, certain non-anesthetic up to its lethal concentration and anesthetic halogenated isopropyl methyl ethers have produces convulsions in mice. In still another com been developed. U.S. Pat. No. 3,476,860 describes a parison, it has been found that the isomeric (CHF),C group of halogenated derivatives of fluorinated F-O-CHF, is a weak anesthetic in which deep isopropyl methyl ethers of which two compounds, anesthesia is not obtained and abnormal EEG (electro namely, CF(CF,Cl). CHOCHCl and (CF),CHOCH, encephalographic) and convulsantactivity is observed. Cl, were stated to be anesthetic. That patent also All of the foregoing comparisons between the novel describes the preparation of several other related com 25 fluorinated ether of this invention and several isomeric pounds, for example, (CF),CHOCHF, and (CF)CH ethers further supports the unobvious and unexpected OCHFC. utility of the present invention. Surprisingly and unexpectedly, it has now been The fluoromethyl 1,1,1,3,3,3-hexafluoro-2-propyl found that the present fluoromethyl 1,1,1,3,3,3-hex ether of this invention is a volatile liquid, is non afluoro-2-propyl ether, which was not mentioned in 30 flammable in air at ambient temperatures and has a U.S. Pat. No. 3,476,860, is an outstanding anesthetic lower flammability limit in oxygen of about 11.8 agent. On the other hand, the foregoing two specific volume percent, which is about three times its compounds suggested as anesthetic agents in said anesthetic maintenance concentration in dogs. patent, and several of the other related compounds Fluoromethyl 1,1,1,3,3,3-hexafluor-2-propyl ether is described in said patent, have now been found upon 35 prepared by several methods. In one method, the further testing to have undesirable properties which chloromethyl 1,1,1,3,3,3-hexafluoro-2-propyl ether is mitigate against their use as clinically useful first prepared by the free radical chlorination of anesthetics. 1,1,1,3,3,3-hexafluoro-2-propyl methyl ether and, That is, it has now been found that when ad more preferably, by a photo induced reaction between ministered to dogs in repeated doses for long periods of 40 about 0.5 to about 1 mole of chlorine per mole of the time, the compounds having a chlorinated methyl hexafluoro-2-propyl methyl ether and a temperature of group, for example, (CF)CHOCHCl, are unstable from about 20 C. to about 65° C. The chlorine is then and toxic to the animal, while that compound having a replaced with fluorine in the methyl group. In this difluorinated methyl group, for example, (CFa),CH replacement reaction, the chloromethyl ether is OCHF, is convulsant. The monochlorinated com 45 reacted with from about 1 to about 3 molar equivalents pound, (CF),CHOCHFCl, also produces opisthotonus of dry potassium fluoride in the presence of a mutual in mice. On the other hand, the present fluoromethyl solvent, for example, an organic solvent such as 1,1,1,3,3,3-hexafluoro-2-propyl ether exhibits out tetrahydrothiophene 1, 1-dioxide, under essentially an standing anesthetic properties over repeated and long hydrous conditions and a temperature of from about term dosage administration in dogs. Consequently, the SO 80 C to about 180 C. present compound has an unexpected and unobvious Another method of preparation of the present utility not exhibited by those compounds mentioned in anesthetic compound involves the reaction of the cor U.S. Pat. No. 3,476,860. responding methyl ether and bromine trifluoride in ac Although the present inventors are not to be bound cordance with a general procedure disclosed by Yu by theory, it is believed that the instability and toxicity 55 minov et. al., Zh. Obshch. Khim., Vol. 37, pages of the chlorinated ether, (CF)CHOCHCl, is due to 375-80 (1967); Chem. Abstracts, Vol. 67, No. 43,357x. the hydrolysis or breakdown of this compound to the In this reaction, fluoromethyl 1,1,1,3,3,3hexafluoro-2- reaction products formaldehyde, hydrochloric acid and propyl ether is prepared from 1,1,1,3,3,3-hexafluoro-2- hexafluoroisopropanol. This toxicity is believed to be propyl methyl ether and from about 0.5 to about 1.0 due primarily to the formation of the formaldehyde and 60 molar equivalent of bromine trifluoride, preferably hydrochloric acid since upon intravenous administra about two-thirds of a molar equivalent, by refluxing at . tion of hexafluoroisopropanol to dogs, the latter com about 20 C to about 50 C. pound by itself was not found to be toxic. These reac Still another method of preparation of the present tion products have been found to be formed during anesthetic ether involves the reaction of 1,3- long term dosage administration of the anesthetic, 65 polyfluoro-2-propanol, formaldehyde and hydrogen (CF)CHOCHCl, in an amount of about 170 times fluoride in accordance with a general procedure the amount that the corresponding reaction products described by Weinmayr, U.S. Pat. No. 2,992,276. 3,689,571 3 4 Surprisingly and unexpectedly, the compound of the minutes. Thereafter, the exothermic reaction was al present invention cannot be prepared by the halogen lowed to proceed autogeneously under partial reflux replacement methods described in examples 3 and 4 of (hydrogen chloride emitted) employing a Dry Ice con U.S. Pat. No. 3,476,860, which involve the reaction of densor. The reaction product was washed successively the corresponding chlorinated ether and antimony 5 with cold water, a small amount of aqueous sodium trifluoride. That is, the fluoromethyl 1,1,1,3,3,3-hex bisulfite and cold water made slightly alkaline with afluoro-2-propyl ether cannot be prepared by the reac sodium hydroxide. The washed product weighed 478 tion of (CF),CHOCH2Cl and antimony trifluoride as is grams. It was dried by azeotropic distillation and then taught in said patent for the preparation of the cor fractionally distilled at 747 mm. Hg. A forerun of 79 responding (CF)CHOCHF, and (CF)CHOCHFC). 10 grams, b 65-77.2 C, was first obtained. The next 281 In general, the anesthetic compound of this invention grams, b 77.2-77.3 C, was chloromethyl 1,1,1,3,3,3- is administered by the inhalation route to warm hexafluoro-2-propyl ether of 99.8 percent purity by . blooded, air breathing animals in an amount of from about 1 percent to about 5 percent by volume in admix gas liquid chromatography (GLC) and with a density of ture with from about 99 percent to about 95 percent by 5 23 C of about 1.517. The CHC-O-CH(CF) struc volume of oxygen or a gaseous mixture containing ox ture was confirmed by a proton nuclear magnetic ygen in sufficient amount to support respiration. resonance (NMR) spectrum. Although specific methods of administration of the EXAMPLE 2 fluoromethyl 1,1,1,3,3,3-hexafluoro-2-propyl ether as an anesthetic agent are described herein, it will be un 20 Chloromethyl 1,1,1,3,3,3-Hexafluoro-2-propyl derstood that this compound is not limited to any par Ether. ticular method of administration. Thus, the fluorinated Dry chlorine gas (685 grams, 9.66 moles) was bubbled ether of this invention can be admixed with one or at an average rate of 31 grams per hour into methyl more other anesthetic agents in order to achieve ad 1,1,1,3,3,3-hexafluoro-2-propyl methyl ether (2712 vantages in administration, degree of relaxation, safety 25 grams, 14.9 moles) at 20 to 25°C with illumination by and the like.
Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • General Anesthetic Actions on GABAA Receptors Paul Garcia, Emory University Scott E
    General Anesthetic Actions on GABAA Receptors Paul Garcia, Emory University Scott E. Kolesky, Emory University Andrew Jenkins, Emory University Journal Title: Current Neuropharmacology Volume: Volume 8, Number 1 Publisher: Bentham Science Publishers | 2010-03, Pages 2-9 Type of Work: Article | Final Publisher PDF Publisher DOI: 10.2174/157015910790909502 Permanent URL: http://pid.emory.edu/ark:/25593/fkg4m Final published version: http://www.eurekaselect.com/71259/article Copyright information: ©2010 Bentham Science Publishers Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution 2.5 Generic License ( http://creativecommons.org/licenses/by/2.5/), which permits distribution, public display, and publicly performance, distribution of derivative works, making multiple copies, provided the original work is properly cited. This license requires credit be given to copyright holder and/or author. Accessed September 28, 2021 5:01 PM EDT 2 Current Neuropharmacology, 2010, 8, 2-9 General Anesthetic Actions on GABAA Receptors Paul S. Garcia, Scott E. Kolesky and Andrew Jenkins* Departments of Anesthesiology and Pharmacology, Emory University, School of Medicine, Rollins Research Center #5013, 1510 Clifton Rd NE, Atlanta GA, USA Abstract: General anesthetic drugs interact with many receptors in the nervous system, but only a handful of these inter- actions are critical for producing anesthesia. Over the last 20 years, neuropharmacologists have revealed that one of the most important target sites for general
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]
  • Environmentally Acceptable Flame Extinguishants
    ENVIRONMENTALLY ACCEPTABLE FLAME EXTINGUISHANTS J. Douglas Mather, Ph. D. Robert E. Tapscott, Ph.D., Chemical Development Studies, Inc. GlobeTech, Inc. 7636 William Moyers Ave. NE 8200 Montgomery Blvd. NE, #218 Albuquerque, NM 87122 Albuquerque, NM 87109 505-797-9706 505-883-9399 [email protected] [email protected] INTRODUCTION Research geared to the identification and testing of environmentally friendly extinguishants – specifically compounds with low boiling points suitable for use in cold environments - is sponsored by the National Institute of Standards and Technology and the Next Generation Fire Suppression Technology Program. Low temperature conditions are a characteristic of aircraft in-flight at higher altitudes. Fire suppression agents with lower boiling points are expected to disperse more rapidly and uniformly than higher boiling agents. A broad review of chemical families identified many with potential to meet the restrictive list of requirements for a suitable halon replacement. This subsequent chemical selection effort builds on several prior projects and guidance from in depth assessment of a wide range of chemical families [1, 2., 3, 4, 5, 6] Chemical families examined as potential sources of halon 1301 alternatives covered a broad range of elements, chemical functionalities. Information relating to environmental persistence, toxicity, flame suppression, reactivity and a number of other factors were considered. The resulting list of chemical families presented as being worthy of continued or initial consideration ranged from brominated carbon based compounds to metal containing compounds. The current focus on low boiling compounds eliminated many of theses down-selected chemical families. The remaining chemical families were reexamined and the higher boiling members eliminated from further consideration.
    [Show full text]
  • De Fármacos Antimaláricos
    Facultad de Química-Farmacia Centro de Bioactivos Químicos TOMOCOMD-CARDD: Un Novedoso Enfoque para el Diseño ‘Racional In- Silico’ de Fármacos Antimaláricos Tesis presentada en opción al grado de Licenciado en Ciencias Farmacéuticas. Autor: Carlos Ricardo Romero Zaldivar Tutores: Prof. Inst., Lic. Yovani Marrero Ponce, M.Sc. Prof. Asist., Lic. Maité Iyarreta Veitía, Ph.D. Santa Clara 2004 RESUMEN Nuevos descriptores moleculares útiles para el diseño “racional in silico” de fármacos han sido aplicados a la modelación de la actividad antimalárica. El cálculo de los nuevos índices moleculares fue implementado en el programa TOMOCOMD-CARDD (TOpological MOlecular COMputer Design-Computed Aided ‘Rational’ Drug Design). Los índices cuadráticos y lineales (estocásticos y no estocásticos) fueron usados junto con el análisis discriminante lineal (ADL) para desarrollar modelos QSAR-ADL que permitan la correcta predicción de la actividad antimalárica. Los modelos obtenidos describen adecuadamente la actividad biológica estudiada y en todos los casos clasifican correctamente más del 90.00% de los compuestos en la serie de entrenamiento. En orden de acceder a la robustez y al poder predictivo de los modelos encontrados, procedimientos de validación cruzada interna y externa fueron utilizados. Estas aproximaciones permiten obtener una adecuada explicación de la actividad antimalárica basado en rasgos estructurales evidenciando el rol preponderante de los enlaces de hidrógenos, la presencia de heteroátomos y de las propiedades relacionadas con el tamaño molecular en las interacciones con los sitios dianas antimaláricos. Posteriormente, los modelos desarrollados fueron usados en la simulación de una búsqueda virtual de inhibidores de la farnesil-transferasa (H-Ras) con actividad antimalárica; 84.61% de los inhibidores de la H-Ras usados en esta búsqueda virtual fueron correctamente clasificados por las modelos QSAR-ADL, indicando la habilidad del método TOMOCOMD-CARDD para el descubrimiento de nuevos compuestos líderes con nuevos mecanismos de acción.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2019 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Comparative Toxicity of Isoflurane, Halothane, Fluroxene and Diethyl Ether in Human Volunteers
    COMPARATIVE TOXICITY OF ISOFLURANE, HALOTHANE, FLUROXENE AND DIETHYL ETHER IN HUMAN VOLUNTEERS WENDELL C. STEVENS, M.D., E.I. ECEn, u, M.D., THOMAS A. JoAs, M.D., THOMAS H. CnOMWELL, M.D., ANNE WHITE, M.A., AND WILLIAM M. DOLAN, M.D. INTRODUCTION ALTHOUC~ SEVEnAL STUDIES have examined the hepatorenal iniury that may occur in man following exposure to anaesthetic drugs, most are tainted by the presence of other medications, the concomitant stress imposed by the operation or the prior existence of hepatic or renal disease. Other studies have failed to measure anaes- thetic dose (alveolar or arterial concentrations) and the duration of anaesthetic exposure, although such measurements are necessary to quantitate the imposed time-dose stress. During our studies of the effects of various anaesthetics on cardiorespiratory function 1-7 we also evaluated the effects of these anaesthetics on subsequent hepatic and renal function. These measurements were made in healthy, young human volunteers and were uncomplicated by prior medication or concomitant operation. Anaesthesia was prolonged and at times profound. We present the results of the hepatic, renal and haematological studies in the following report. The findings suggest that small but significant differences exist among anaesthetics in their abilities to produce adverse effects. However, the changes seen were minimal, even with those agents which caused abnormalities. METHODS Many of the details of the methods used in this study have been described previously and only additions or deviations from prior protocols will be noted. 1-7 Briefly, studies were made on healthy volunteers between 21 and 30 years of age.
    [Show full text]
  • Caenorhabditis Elegans (Genetics/Mutations/Anesthesia) PHIL G
    Proc. Natl. Acad. Sci. USA Vol. 87, pp. 2%5-2969, April 1990 Medical Sciences Multiple sites of action of volatile anesthetics in Caenorhabditis elegans (genetics/mutations/anesthesia) PHIL G. MORGAN*t, MARGARET SEDENSKY*, AND PHILIP M. MENEELY* *Department of Anesthesiology, University Hospitals of Cleveland and Case Western Reserve University, Cleveland, OH 44106; tFred Hutchinson Cancer Research Center, Seattle, WA 98104 Communicated by Harold Weintraub, January 22, 1990 (receivedfor review November 2, 1989) ABSTRACT The mechanism and site(s) of action of vola- low doses of anesthetic the animals become "excited," tile anesthetics are unknown. In all organisms studied, volatile moving more than animals not exposed to anesthetics. As the anesthetics adhere to the Meyer-Overton relationship-that anesthetic concentrations are increased, the animals next is, a in-n plot of the oil-gas partition coefficients versus the become very uncoordinated, and at higher doses they are potencies yields a straight line with a slope of -1. This immobilized. When removed from the anesthetics the nem- relationship has led to two conclusions about the site of action atodes quickly regain mobility and return to their normal of volatile anesthetics. (i) It has properties similar to the lipid phenotype. Mutations in two genes, unc-79 and unc-80, used to determine the oil-gas partition coefficients. (a) All confer altered responses to volatile anesthetics, in addition to volatile anesthetics cause anesthesia by affecting a single site. In an altered motor phenotype. When not in the presence of Caenorhabditis elegans, we have identified two mutants with anesthetics, both these mutants are described as "fainters." altered sensitivities to only some volatile anesthetics.
    [Show full text]
  • Author Index
    Author Index The numbers shown in square brackets are the numbers of the references in the bibliography. Page numbers in italiC<J refer to the bibliography" Abajian, J., Jr., Brazell, E. Ahlgren, I., Aronsen, K. F. Allaria, R, Galligari, G., H., Dente, G. A., Mills, 181,228 Bottani, G., Castelli, S. E. L. 306, 320 -- Ericsson, B., Fajgelj, 174, 176, 202, 203, 228 - see Mazuzan, J. E. 169, A. 181,228 Allen, C. R., see Walker, J. 171,235 - see Belfrage, S. 58, 66 A. 166, 172, 175, 177, - see Shinozaki, T. 36,51, Ahlgren, L., see Belfrage, S. 201, 204, 206, 207, 240 75, 169, 172, 175, 176, 512,526 - see Wilson, R. D. 112, 177,238 Ahlmark, A., Forssman, S. 122 Abbott 77 350,354 Allen, G. D., Ward, R. J., Abbott, B. C., Mommaerts, Aikawa, J. K., see Virtue, Perrin, E. R 46, 66 W. F. H. M. 228 R. W. 247,253 - see Ward, R. J. 240 Abboud, F. M., see Caffrey, Akester, J. M., Brody, M. J. Allen, J. G., see Adams, W. J. A. 53,67,184,230 183,228 F. 492,499 Abel, F. L., Waldhausen, J. Albers, C., Brendel, W., Allison, A. C., Nunn, J. F. A. 118 Usinger, W. 281,284 63,66 - see Sutherland, A. 160, Albert, S. N., Jain, R. C., Allweis, C., Magnes, J. 239 Shadid, .J. N. 200, 228 394,395,404 Abere, J. F., see Bovey, F. Albin, M. S., Horrocks, L. - see Barkai, A. 395, 404 20, 30 A., Kretchmer, E. 12,.30 Allweis, C.
    [Show full text]